Key Highlights
- Loss per share was USD 0.73.
- Net loss was USD 6.79 million, compared with USD 4.25 million.
- Total operating expenses were USD 10.03 million, compared with USD 4.41 million.
- Cash and cash equivalents were USD 282.7 million at September 30, 2026.
Lisata Therapeutics (NASDAQ:LSTA) reported a net loss of USD 6.79 million for the third quarter of 2026, compared with USD 4.25 million in the prior-year quarter. Loss per share was USD 0.73.
For the nine months ended September 30, 2026, the net loss was USD 14.21 million, compared with USD 13.63 million. The filing states that on September 17, 2026, the company completed a stock-for-stock Business combination with Marea Therapeutics, Inc.
Operating Expenses
Research and development expenses were USD 5.21 million, compared with USD 1.96 million, and general and administrative expenses were USD 4.82 million, compared with USD 2.46 million. Total operating expenses were USD 10.03 million, compared with USD 4.41 million, and the operating loss was USD 10.03 million, compared with USD 4.41 million.
For the nine months, Research and Development expenses were USD 6.99 million, compared with USD 6.82 million, and general and administrative expenses were USD 11.97 million, compared with USD 8.39 million. Total operating expenses were USD 18.96 million, compared with USD 15.20 million.
Other Income and Net Loss
Investment income, net, was USD 273 thousand, compared with USD 183 thousand, and other expense, net, was USD 3.06 million, compared with USD 18 thousand. The net loss before benefit from income taxes was USD 12.81 million, compared with USD 4.25 million.
The benefit from income taxes was USD 6.03 million, and the net loss was USD 6.79 million. For the nine months, the net loss before benefit from income taxes was USD 20.62 million, compared with USD 14.59 million, and the benefit from income taxes was USD 6.41 million, compared with USD 962 thousand.
Cash and Liquidity
The filing states that as of September 30, 2026, the company had an accumulated Deficit of USD 578.9 million and cash and cash equivalents of USD 282.7 million, which includes USD 212.1 million in net proceeds received in the 2026 private Placement and USD 72.9 million acquired in the acquisition. Cash and cash equivalents were USD 16.0 million at the prior Balance Sheet date.
The Acquisition accounting reports in-process research and development of USD 292.9 million among the Assets acquired. The cover of the filing reports 10,804,066 shares of common stock outstanding.
The filing states that on September 17, 2026 the company acquired 100% of the Equity interests of Marea Therapeutics, Inc. pursuant to a Merger agreement. At the closing, the company issued to the stockholders of Marea 1,793,129 shares of common stock and 211,365.213 shares of Series C Preferred Stock, each of which is convertible into 1,000 shares of common stock, subject to approval by the company's stockholders.
Concurrent with the acquisition, on September 18, 2026, the company completed a private placement financing through the sale of shares of Series C Preferred Stock, resulting in gross proceeds of USD 225 million. The filing states that Marea's results are included in the company's results from September 17, 2026.
Lisata Therapeutics Q3 2026 Earnings: Key Takeaways
Lisata Therapeutics reported a third quarter 2026 net loss of USD 6.79 million and a loss per share of USD 0.73. Cash and cash equivalents were USD 282.7 million at September 30, 2026.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...